QIBA Dynamic Susceptibility Contrast (DSC-MRI) Biomarker Committee (BC) Meeting

Wednesday, August 9, 2023, at 11 a.m. (CT)

Draft Meeting Summary

Participants RSNA

Ona Wu, PhD (Co-chair) Lisa Cimino, RT Sina Nazemi, MD Susan Stanfa Nima Ameli, MD Zhaoyang Fan, PhD Gudrun Zahlmann, PhD

Michael Boss, PhD

The following topics were discussed:

- DSC-MRI Profile Amendments
- White paper

Action items

- Staff had distributed the DSC-MRI Profile for BC review of the following amendments
 - Section 3.9: Specifications for contrast injection rate that had inadvertently been excluded during edits prior to Public Comment were added back in
 - Section 3.11: Reference to QIBA Profile: CT Tumor Volume Change for Advanced Disease to justify volume ranges was added
 - Section 4.7: Minimum size for region-of-interest for measuring values in normal appearing white matter was reduced to 2X2cm² to align with the methods and data analysis (Prah article) on which the Profile Claims are based
 - Technologist Checklist: specifications for contrast injection rate that had inadvertently been excluded during edits prior to Public Comment were added back in
- Statistical aspects of the Profile Claim were discussed and will be incorporated into the white paper

Next Steps

- Staff to send out Profile (maintenance version) amendments ballot to eligible DSC-MRI BC voters; CC vote deemed unnecessary for these revisions
 - Clean, updated version of Profile to be posted to QIBA Wiki DSC-MRI Committee page following BC approval
- Checklist based on the DSC-MRI Profile and adapted for use by clinical trial sites to be developed for GABLE study
- White paper to be finalized and submitted to Radiology before Dec. 2023
- The next DSC-MRI BC meeting will be held on Wednesday, September 13, 2023, at 11:00 11:50 a.m. CT

Participants are welcome to contact RSNA staff at qiba@rsna.org if their attendance is not reflected in meeting summaries.